Wu Xiang, Xu Qing-Jiang, Chen Ping-Zhou, Yu Chen-Bo, Ye Lie-Fu, Li Tao
Provincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, People's Republic of China.
Department of Urology, Fujian Provincial Hospital, Fuzhou 350001, People's Republic of China.
Pharmgenomics Pers Med. 2020 Jun 4;13:181-188. doi: 10.2147/PGPM.S245086. eCollection 2020.
The purpose of this study was to investigate the association between single nucleotide polymorphisms (SNPs) of CYP17A1, CYB5A and the efficacy of abiraterone acetate treatment in patients with castration-resistant prostate cancer (CRPC).
Data were collected from 58 CRPC patients who had been treated with abiraterone acetate/prednisone (AA/P). The SNPs rs743572 and rs10883783 on CYP17A1 and SNPs rs1790834 and rs1790858 on CYB5A were assayed, and their relationship with prostate-specific antigen (PSA) response in patients after AA/P treatment, overall survival (OS) and progression-free survival (PFS) were analyzed by logistic regression, Cox regression, Kaplan-Meier and Log rank analyses.
The SNP rs1790834 on CYB5A showed significant association with PSA response in CRPC patients treated with AA/P ( < 0.05), but rs743572, rs10883783 and rs1790858 did not. The rs1790834 variant significantly decreased both PFS and OS ( < 0.05).
The CYB5A rs790834 genotype is a novel SNP related to CRPC and may be used as a biomarker for CRPC treatment.
本研究旨在探讨细胞色素P450 17α-羟化酶1（CYP17A1）、细胞色素b5（CYB5A）的单核苷酸多态性（SNP）与醋酸阿比特龙治疗去势抵抗性前列腺癌（CRPC）患者疗效之间的关联。
收集58例接受醋酸阿比特龙/泼尼松（AA/P）治疗的CRPC患者的数据。检测CYP17A1上的SNP rs743572和rs10883783以及CYB5A上的SNP rs1790834和rs1790858，并通过逻辑回归、Cox回归、Kaplan-Meier和对数秩分析来分析它们与AA/P治疗后患者前列腺特异性抗原（PSA）反应、总生存期（OS）和无进展生存期（PFS）的关系。
CYB5A上的SNP rs1790834与接受AA/P治疗的CRPC患者的PSA反应显著相关（<0.05），但rs743572、rs10883783和rs1790858则不然。rs1790834变异显著降低了PFS和OS（<0.05）。
CYB5A rs1790834基因型是一种与CRPC相关的新型SNP，可能用作CRPC治疗的生物标志物。
